GMP certification requirements in Central American countries

Home/Reports | Posted 01/10/2021 post-comment0 Post your comment

Before submitting documentation for the marketing authorization of a medicinal product in several countries in Latin America, there are several requirements that have to be taken into consideration

147 AA010665

In particular, biopharmaceuticals are complex as their active pharmaceutical ingredient (API) is manufactured using living systems. In turn, this leads to complex manufacturing processes. It has revealed that we are well on the way to global harmonization of GMP standards that will help bring these products to more people across the globe [1].

This article briefly presents the requirements for the good manufacturing practice (GMP) certification for market authorization in the RTCA signatory countries: Costa Rica, El Salvador, Guatemala, Honduras, Nicaragua and Panama.

The Central American Technical Regulation (RTCA) establishes the conditions and requirements under which the sanitary registration of natural medicinal products for human use for commercialization. This regulation applies to natural medicinal products for human use manufactured or imported by natural persons or companies for commercialization in the States Parties of the region Central American.

The following is a brief description of the requirements for the submission of GMP certificates in marketing authorization applications for medicinal products from RTCA signatory countries.

The authorities of each of these countries follow the requirements set by the harmonized RTCA regulation for drug product market authorization applications. Each of them requires the presentation of the GMP certificate for the drug product and accepts the document issued by the authority of the country where the manufacturing site is located.

It is provided by the RTCA that the local authorities may inspect the plants in question if they deem necessary; or recognize the certification of authorities considered to be of high surveillance by the World Health Organization (WHO).

This article is the third of a series of four articles on the certification of GMP requirements in different countries in Latin America.

Related articles
GMP certification requirements in Chile, Cuba and Venezuela

GMP certification requirements in Andean Community countries

GMP certification requirements in Argentina, Brazil and Mexico

Biopharmaceuticals and biosimilars: challenges in manufacture, regulation and international harmonization of GMP


The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View this week’s headline article: Política de sustitución de biosimilares de Canadá: efectos sobre la competencia y seguridad del paciente

Browse the news in the Latin American Forum!

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.


Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Vea el artículo principal de esta semana: Política de sustitución de biosimilares de Canadá: efectos sobre la competencia y seguridad del paciente

Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa. 

1. Sia CH, Sia MK, Chan LW. Global challenges in the manufacture, regulation and international harmonization of GMP and quality standards for biopharmaceuticals. Generics and Biosimilars Initiative Journal (GaBI Journal). 2020;9(2):52-63. doi:10.5639/gabij.2020.0902.010

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2021 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010